OncLive TV

Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer

January 22nd 2015

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

Dr. Scott Rowley on Allogeneic Stem Cell Transplant

January 21st 2015

Scott Rowley, MD, the Chief of John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.

Dr. Stewart on the Safety Profile of Carfilzomib in Multiple Myeloma Patients

January 20th 2015

A. Keith Stewart, MBChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Dr. Donna McNamara on PARP Inhibitors for Ovarian Cancer Treatment

January 20th 2015

Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, talks about the benefits of PARP inhibitors for women with BRCA1 or BRCA2-mutated, platinum-sensitive ovarian cancer.

Dr. Muro on Pembrolizumab for Gastric Cancer

January 19th 2015

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Dr. Laura Dawson on HCC Challenges

January 19th 2015

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, talks about the challenges in treating hepatocellular carcinoma (HCC).

Dr. Alvarnas on Stem Cell Transplant for HIV-Associated Lymphoma

January 15th 2015

Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.

Dr. Goy Discusses the Impact of the Roche/Foundation Medicine Partnership

January 14th 2015

Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche's recent acquisition of the molecular testing company Foundation Medicine.

Dr. Wolchok on Remaining Questions Regarding Immunotherapies in Melanoma

January 13th 2015

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Dr. Cookson on Ideal Bladder Cancer Biomarkers

January 13th 2015

No one biomarker is effective for all types of bladder cancer, says Michael Cookson, MD, a professor and chairman of the Department of Urology at the University of Oklahoma College of Medicine.

Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AML

January 9th 2015

Dr. Advani Compares Inotuzumab and Blinatumomab for ALL

January 8th 2015

Anjali Advani, MD ,staff physician, Department of Hematologic Oncology and Blood Disorders, Director, Inpatient Leukemia Program, Taussig Cancer Institute, associate professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, compares inotuzumab ozogamicin, a CD22 monoclonal antibody, to blinatumomab, a CD19 bi-specific anti-CD19/CD3 antibody for the treatment of acute lymphoblastic leukemia (ALL).

Dr. Sieber on the CHAARTED Trial

January 8th 2015

Paul Sieber, MD, principal investigator for clinical trials with Lancaster Urology, talks about the CHAARTED trial, which examines chemohormonal therapy versus androgen ablation for extensive disease in prostate cancer.

Dr. Fisher on Bortezomib/R-CHOP Combo for Mantle Cell Lymphoma

January 7th 2015

Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

Dr. Arteaga on PI3K Pathway Inhibitors

January 6th 2015

Carlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.

Dr. Langer on Afatinib for Advanced Non-Small Cell Lung Cancer

January 5th 2015

Corey Langer, MD, the director of Thoracic Oncology at the University of Pennsylvania, discuses afatinib, which was approved in 2013 for first line EGFR-mutated advanced non-small cell lung cancer.

Dr. Morgan on the Future of Myeloma Treatment

January 2nd 2015

Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

December 31st 2014

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Dr. Ghobrial on Antibodies for Multiple Myeloma Treatment

December 29th 2014

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Dr. Gomella on Labeling Low-Risk Prostate Cancer

December 26th 2014

Leonard Gomella, MD, urology specialist from Jefferson University, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.